glp-1 news today october 20 2025 Perspectives from employers on the costs and issues associated with covering agonists for weight loss GLP-1 Pipeline Update: August 2025
Description
Platforms like MeAgain's GLP-1 app address this problem by combining no-markup compounded medications with daily tracking tools that build consistency over months
Currently, tirzepatide is the most promising listed incretin analogue
First came the dramatic before-and-after photos
How is tirzepatide different from semaglutide
Reported side effects include worsening of depression, anxiety, apathy, and, in rare cases suicidality, especially in populations using GLP-1RAs for weight loss without metabolic disease [30,42]
